Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors

Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The s...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of nuclear medicine (1978) Vol. 55; no. 10; p. 1650
Main Authors: Morgat, Clément, Mishra, Anil Kumar, Varshney, Raunak, Allard, Michèle, Fernandez, Philippe, Hindié, Elif
Format: Journal Article
Language:English
Published: United States 01.10.2014
Subjects:
Breast Neoplasms - diagnosis
Breast Neoplasms - drug therapy
Female
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Male
Peptides - chemistry
Positron-Emission Tomography - methods
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - drug therapy
Receptors, Bombesin - chemistry
Receptors, Neuropeptide Y - chemistry
Receptors, Neurotensin - chemistry
Tomography, X-Ray Computed - methods
neurotensin
receptor
neuropeptide Y
radiopharmaceutical
cancer
molecular imaging
PET
bombesin
peptide/neuropeptide
ISSN:1535-5667, 1535-5667
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1535-5667
1535-5667
DOI:10.2967/jnumed.114.142000